Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2^pos Breast Cancer

Figure 5

Dual treatment significantly suppresses HER-2 expression compared with single treatments. SKBR-3 cells were seeded at per mL and were left either untreated (No Rx) or treated with Th1 cytokines (5 ng/mL), sunitinib (10 μM), or sunitinib and Th1 cytokines (both) for 72 hours. Cells were harvested and stained with APC-labeled anti-HER-2 antibody and evaluated by flow cytometry using a 642 nm excitation laser. (a) Histogram analysis of HER-2 expression from a single representative experiment. (b) Composite data analysis of mean channel fluorescence from three separate experiments for each treatment group. Statistical significance was determined by one-way ANOVA: (, ) followed by Tukey post hoc analysis. Significance was set at , , and . Error bars represent the standard error of the mean.

(a)

(b)